Maze Therapeutics
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership rose 3.2 percentage points.
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 112.39% +3.17pp
- Institutions
- 199 -1
- As of
- 2026/Q3 vs. prior period
Holder types
Top holders as of 2026-06-30
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 15 buys · 35 sells
| Name | Role | Stake |
|---|---|---|
| Jason Coloma | Chief Executive Officer | 0.37% |
| Sekar Kathiresan | Former Independent Director | 0.19% |
| Atul Dandekar | Chief Strategy & Business Officer | 0.06% |
| Charles Homcy | Director | 0.06% |
| Jonathan Lim | Independent Director | 0.04% |
| Amy Bachrodt | Former Officer | 0.02% |
| Courtney Phillips | General Counsel | 0.01% |
| Daniel Spiegelman | Independent Director | -- |
| Richard Scheller | Independent Director | -- |
| Paula Johnson | Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-01 | Jason Coloma | Chief Executive Officer | Automatic Disposition | -34,501 | $30.10–31.05 |
| 2026-10-28 | Atul Dandekar | Chief Strategy & Business Officer | Derivative Exercise and Sale | -7,500 | $10.42–32.07 |
| 2026-09-30 | Jason Coloma | Chief Executive Officer | Automatic Disposition | -34,501 | $27.02–27.02 |
| 2026-09-30 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -16,141 | $10.42–26.93 |
| 2026-09-28 | Atul Dandekar | Chief Strategy & Business Officer | Derivative Exercise and Sale | -7,500 | $10.42–27.06 |
| 2026-09-03 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Automatic Disposition | -9,705 | $26.22 |
| 2026-09-02 | Jason Coloma | Chief Executive Officer | Open Market Disposition | -22,638 | $25.77–27.12 |
| 2026-09-02 | Atul Dandekar | Chief Strategy & Business Officer | Open Market Disposition | -6,434 | $25.81–27.12 |
| 2026-09-02 | Courtney Phillips | General Counsel | Open Market Disposition | -3,993 | $25.78–27.12 |
| 2026-09-02 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Open Market Disposition | -10,295 | $25.78–27.12 |
| 2026-09-01 | Courtney Phillips | General Counsel | Intent to Sell (Form 144) | -4,144 | $26.54 |
| 2026-09-01 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Intent to Sell (Form 144) | -10,685 | $26.53 |
| 2026-08-31 | Jason Coloma | Chief Executive Officer | Automatic Disposition | -34,501 | $26.29–26.31 |
| 2026-08-31 | Jason Coloma | Chief Executive Officer | Derivative Exercise and Retained | +50,000 | -- |
| 2026-08-31 | Atul Dandekar | Chief Strategy & Business Officer | Derivative Exercise and Retained | +12,500 | -- |
| 2026-08-31 | Courtney Phillips | General Counsel | Derivative Exercise and Retained | +11,000 | -- |
| 2026-08-31 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Derivative Exercise and Sale | -16,141 | $10.42–26.36 |
| 2026-08-31 | Harold Bernstein | President of Research & Development and Chief Medical Officer | Derivative Exercise and Retained | +20,000 | -- |
| 2026-08-27 | Atul Dandekar | Chief Strategy & Business Officer | Derivative Exercise and Sale | -7,500 | $10.42–27.58 |
| 2026-08-12 | Paula Johnson | Director | Other Derivative Acquisition | +36,000 | $27.67 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Maze Therapeutics discussion 0 comments